New Video Alert: Promising Developments in Schizophrenia Treatment with Dr. Kakar

🎥 New Video Alert: Promising Developments in Schizophrenia Treatment with Dr. Kakar

In our continued commitment to long-term schizophrenia research, Segal Trials is excited to share an exclusive video interview with Dr. Kakar, our esteemed CSO and Medical Director at Segal Trials. As a lead investigator for the groundbreaking study on KarXT, he explains the latest data collected, and how it's showing promise for the treatment of schizophrenia.

According to new data, KarXT (xanomeline-trospium) shows a positive long-term metabolic profile in adults with schizophrenia, with patients experiencing metabolic stability or improvements over a 52-week course of treatment. “Unlike current schizophrenia treatments that are often associated with a variety of adverse events such as weight gain and hyperlipidemia, KarXT offers a new and unique mechanism of action that does not directly block dopamine receptors,” said Dr. Rishi Kakar, Chief Scientific Officer and Medical Director of Segal Trials. The phase 3 EMERGENT program data revealed significant weight reductions and stable metabolic parameters, positioning KarXT as a promising new treatment for schizophrenia.

Let's explore the future of schizophrenia treatment together!

#SchizophreniaTreatment #MentalHealthInnovation #KarXT #HealthcareLeadership #MedicalResearch #VideoInterview #ClinicalStudies